FDA advisors quit after approval of Alzheimer's medicine
On Monday, US authorities defied an external panel by approving Biogen's Alzheimer's treatment. Now, several of the participants are stepping down.
BY RITZAU, TRANSLATED BY CATHERINE BRETT
Three members of an outside panel that advises the US Food and Drug Administration (FDA) have quit over the past few days.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen to start shipping new Alzheimer's drug in two weeks
For subscribers
.jpg&w=384&q=75)
